A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma.
John P MichaMark A RettenmaierRandy D BohartBram H GoldsteinPublished in: Journal of gynecologic oncology (2022)
The study results suggest that the combination of paclitaxel, carboplatin and metformin is associated with moderate efficacy and a reasonable toxicity profile.